Skip to main content
. Author manuscript; available in PMC: 2020 Jul 10.
Published in final edited form as: Ann Surg Oncol. 2013 Mar 24;20(9):3059–3065. doi: 10.1245/s10434-013-2878-9

FIG. 4.

FIG. 4

Malignant ascitic cells positive for LRP by IHC (+) showed greater resistance/cell viability to treatment with 50 μM carboplatin than malignant ascitic cells negative for LRP by IHC (−) (p = 0.0043). LRP stratification did not identify sensitivity to paclitaxel using cell viability assay (p > 0.05). Cells were more viable in LRP+ patients after combination (50/1,000) treatment than LRP–patient samples (p = 0.045)